Company to host a virtual webinar on PRMT5 data and the synthetic lethality pipeline, including WRN and novel target discovery, today Monday, October 16 at 9.30 am CEST

公司将于10月16日星期一上午9点30分在CEST举办PRMT5数据和合成杀伤力管道（包括WRN和novel target discovery）的虚拟网络研讨会

Presentations include updated data from the lead preclinical program on MTA-cooperative PRMT5 inhibitors

介绍包括来自MTA合作PRMT5抑制剂临床前项目的最新数据

Preclinical studies highlight the potential of Ryvu's synthetic lethality platform based on primary cells

临床前研究强调了基于原代细胞的Ryvu合成致死平台的潜力

Ryvu's partner Menarini presented preclinical data on MEN1703 (SEL24) showing promising anti-tumor activity in B-cell lymphomas, supporting the Phase II clinical program

Ryvu的合作伙伴Menarini提供了MEN1703（SEL24）的临床前数据，显示B细胞淋巴瘤具有良好的抗肿瘤活性，支持II期临床项目

KRAKOW, Poland, Oct. 16, 2023 /PRNewswire/ -- Ryvu Therapeutics (WSE: RVU), a clinical-stage drug discovery and development company focusing on novel small molecule therapies that address emerging targets in oncology, today announced presentations of preclinical data from the PRMT5 program and synthetic lethality platform, as well as preclinical data on MEN1703 (SEL24) in B-cell lymphomas, at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, taking place in Boston, Massachusetts..

波兰克拉科夫，2023年10月16日/PRNewswire/-Ryvu Therapeutics（WSE:RVU），一家专注于解决肿瘤学新兴靶点的新型小分子疗法的临床阶段药物发现和开发公司，今天宣布介绍临床前来自PRMT5计划和合成致死性平台的数据，以及B细胞淋巴瘤中MEN1703（SEL24）的临床前数据，在2023年AACR-NCI-EORTC分子靶点和癌症治疗国际会议上，在马萨诸塞州波士顿举行。。

'We are pleased with preclinical data underscoring the promise of our synthetic lethality platform, as highlighted by our leading preclinical program on PRMT5 inhibitors,' said Krzysztof Brzózka, Ph.D., Chief Scientific Officer of Ryvu Therapeutics. 'With the growing evidence of the potential of PRMT5 as a cancer therapeutic target, we are excited to share updated data on our MTA-cooperative PRMT5 inhibitors showing high selectivity and efficacy in animal tumor models.

Ryvu Therapeutics首席科学官Krzysztof Brzózka博士说：“我们很高兴临床前数据强调了我们合成致死性平台的前景，正如我们在PRMT5抑制剂方面的领先临床前计划所强调的那样。”随着越来越多的证据表明PRMT5作为癌症治疗靶点的潜力，我们很高兴分享有关MTA合作PRMT5抑制剂的最新数据，这些抑制剂在动物肿瘤模型中显示出高选择性和有效性。

Our potentially best-in-class MTA-cooperative PRMT5 inhibitors exhibit significantly improved pharmacokinetics relative to other PRMT5 inhibitors currently in development. Given their in vivo target engagement and remarkable anti-tumor efficacy, we anticipate further development and progression to IND-enabling studies in 2024.

相对于目前正在开发的其他PRMT5抑制剂，我们潜在的一流的MTA合作PRMT5抑制剂表现出显着改善的药代动力学。鉴于其体内目标参与和显着的抗肿瘤功效，我们预计2024年IND的进一步发展和进展。

In addition, we presented our comprehensive primary colorectal cancer (CRC) cell models that not only mirror the molecular profile seen in patient-derived specimens but also surpass industry benchmarks in screenings, making them invaluable for future drug discovery.'.

此外，我们还展示了我们全面的原发性结直肠癌（CRC）细胞模型，这些模型不仅反映了患者来源标本中的分子谱，而且在筛查方面超过了行业基准，使其对未来的药物发现具有不可估量的价值。

Ryvu licensee, Menarini Group, and academic collaborators presented preclinical data on MEN1703 (SEL24), a first-in-class, oral, dual type I PIM/FLT3 inhibitor in B-cell lymphomas, where MEN1703 demonstrated promising anti-tumor activity. These data support the Phase II clinical program of MEN1703 in diffuse large B-cell lymphoma (DLBCL)..

Ryvu被许可人，Menarini集团和学术合作者提供了MEN1703（SEL24）的临床前数据，MEN1703是B细胞淋巴瘤中一流的口服双I型PIM/FLT3抑制剂，其中MEN1703表现出有希望的抗肿瘤活性。这些数据支持MEN1703在弥漫性大B细胞淋巴瘤（DLBCL）中的II期临床计划。。

Details on the poster presentations are as follows:

海报演示文稿的详细信息如下：

Abstract Title: 'Discovery of Novel MTA-cooperative PRMT5 Inhibitors as Targeted Therapeutics for MTAP-deleted Cancers'

摘要标题：“发现新型MTA合作PRMT5抑制剂作为MTAP缺失癌症的靶向治疗药物”

Ryvu has developed potentially best-in-class MTA-cooperative PRMT5 inhibitors with outstanding drug-like physicochemical properties and the ability to block methyltransferase activity of PRMT5 with nanomolar IC50 values. The novel, optimized inhibitors exhibit a significantly improved PK profile, and in addition, the compounds show antitumor efficacy and target engagement in vivo, providing a strong foundation for further development..

Ryvu开发了潜在的一流的MTA合作PRMT5抑制剂，具有出色的药物样物理化学性质，并具有纳摩尔IC50值阻断PRMT5甲基转移酶活性的能力。新型优化抑制剂具有显着改善的PK特征，此外，该化合物在体内显示出抗肿瘤功效和靶标参与，为进一步开发奠定了坚实的基础。。

Abstract Title: 'A Comprehensive Platform for Unraveling the Molecular Mechanisms and Vulnerabilities of Colorectal Cancer: A Step Forward in Target Discovery'

摘要题目：“揭开结直肠癌分子机制和脆弱性的综合平台：目标发现迈出的一步”

Ryvu has pioneered an extensive platform that employs primary colorectal cancer (CRC) models, originated from human intestinal stem cells. This innovative approach enables high-throughput phenotypic assays and CRISPR/Cas9 genomic screenings, surpassing conventional industry standards. The robustness of these models has been confirmed through Ryvu's proprietary ranking algorithm, which identifies potential synthetic lethal drug targets, particularly in KRAS-driven cells..

Ryvu开创了一个广泛的平台，采用源自人类肠道干细胞的原发性结直肠癌（CRC）模型。这种创新的方法能够实现高通量表型分析和CRISPR/Cas9基因组筛选，超过传统的行业标准。这些模型的稳健性已通过Ryvu专有的排名算法得到证实，该算法可识别潜在的合成致死药物靶标，特别是在KRAS驱动的细胞中。。

Abstract Title: 'MEN1703/SEL24, A Potent PIM Inhibitor, Demonstrates Promising Anti-Tumor Activity in Activated B Cell Like DLBCL, Mantle Cell Lymphoma and Marginal Zone Lymphoma Cells'

摘要标题：'MEN1703/SEL24，一种有效的PIM抑制剂，在活化的B细胞如DLBCL，套细胞淋巴瘤和边缘区淋巴瘤细胞中表现出有希望的抗肿瘤活性'

Pharmacological inhibition with MEN1703 (SEL24), a first-in-class, oral, dual type I PIM/FLT3 inhibitor shows anti-proliferative effects in B cell lymphomas of various histotypes. Importantly, MEN1703 was effective in lymphoma cells resistant to other treatments inducing apoptosis in most cell lines.

MEN1703（SEL24）（一种一流的口服双I型PIM/FLT3抑制剂）的药理学抑制作用在各种组织型的B细胞淋巴瘤中显示出抗增殖作用。重要的是，MEN1703在对大多数细胞系诱导凋亡的其他治疗有抗性的淋巴瘤细胞中有效。

RNA-Seq indicated that the molecule modulates the transcriptome of highly responsive DLBCL cell lines differently from other, poorly responsive cells, providing clues to mechanisms involved in sensitivity to PIM inhibitors and supporting potential in treating B-cell lymphomas..

RNA-Seq表明该分子调节高反应性DLBCL细胞系的转录组不同于其他反应性差的细胞，为涉及对PIM抑制剂敏感性和支持治疗B细胞淋巴瘤的潜力提供了线索。。

Posters are available on the Ryvu corporate website.

海报可在Ryvu公司网站上找到。

Webinar on PRMT5 and synthetic lethality pipeline, including WRN project and target discovery efforts

PRMT5和合成杀伤力管道网络研讨会，包括WRN项目和目标发现工作

Ryvu will host a webinar today at 9:30 am CEST to discuss the PRMT5 data. To join the webcast, please register here: https://bit.ly/3RL1YWp. A recording from the webinar will be available on the 'Presentations' section of the Ryvu website.

Ryvu将于CEST上午9:30主持网络研讨会，讨论PRMT5数据。要加入网络广播，请在这里注册：https://bit.ly/3RL1YWp.网络研讨会的录音将在Ryvu网站的“演示”部分提供。

About Ryvu Therapeutics

关于Ryvu疗法

Ryvu Therapeutics is a clinical-stage drug discovery and development company focused on novel small-molecule therapies that address emerging targets in oncology. Internally discovered pipeline candidates make use of diverse therapeutic mechanisms driven by emerging knowledge of cancer biology, including small molecules directed at kinases, synthetic lethality and immuno-oncology targets..

Ryvu Therapeutics是一家临床阶段药物发现和开发公司，专注于解决肿瘤学新兴目标的新型小分子疗法。内部发现的管道候选者利用由癌症生物学新兴知识驱动的各种治疗机制，包括针对激酶，合成致死率和免疫肿瘤学靶标的小分子。。

Ryvu's most advanced programs are RVU120 — a selective CDK8/CDK19 kinase inhibitor with potential for the treatment of hematological malignancies and solid tumors currently in phase I clinical development for the treatment of acute myeloid leukemia and myelodysplastic syndrome, and phase I/II for the treatment of r/r metastatic or advanced solid tumors — and SEL24 (MEN1703), a dual PIM/FLT3 kinase inhibitor licensed to the Menarini Group.

Ryvu最先进的项目是RVU120-一种选择性CDK8/CDK19激酶抑制剂，可用于治疗血液系统恶性肿瘤和实体瘤目前正处于I期临床开发阶段，用于治疗急性髓性白血病和骨髓增生异常综合征，I/II期用于治疗r/r转移性或晚期实体瘤-和SEL24（MEN1703），授予Menarini组的双重PIM/FLT3激酶抑制剂。

Ryvu Therapeutics has signed multiple partnering and licensing deals with global companies, including BioNTech, Exelixis, Menarini and Merck..

Ryvu Therapeutics已与全球公司签署了多项合作和许可协议，包括BioNTech，Exelixis，Menarini和Merck。。

The Company was founded in 2007 and is headquartered in Kraków, Poland. Ryvu is listed on the Warsaw Stock Exchange and is a component of the mWIG40 index. For more information, please see www.ryvu.com.

该公司成立于2007年，总部设在波兰克拉科夫。Ryvu在华沙证券交易所上市，是mWIG40指数的一个组成部分。有关更多信息，请参阅www.ryvu.com。

SOURCE Ryvu Therapeutics

来源Ryvu疗法